NCT06178211View on ClinicalTrials.gov

Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

November 30, 2026

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Immunotherapy: Adebrelimab

Adebrelimab 1200mg Q3W

DRUG

chemotherapy: carboplatin plus nab-paclitaxel

carboplatin plus nab-paclitaxel

Trial Locations (1)

Unknown

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Chest Hospital

OTHER